Articles tagged with Prostate Cancer
Scientists at the University of York have discovered a cancer-inducing DNA realignment in human prostate cancer stem cells that can lead to more effective therapies targeting the root cause of the disease. This breakthrough has challenged previous understanding of solid cancers and offers new opportunities for targeted treatments.
Genetic factors such as BRCA2 and HOXB13 play a crucial role in predicting high-risk prostate disease. Lifestyle factors including diet, exercise and geographic origin are also risk factors for PCa.
A study found that genetic testing can help identify BPH patients at higher risk of developing prostate cancer. Ten single nucleotide polymorphisms were linked to PCa risk, with one marker showing a strong association.
A study by Sanford-Burnham researchers found that Siah2 keeps androgen receptors constantly active in prostate cancer cells, enabling them to survive treatment. Inhibiting Siah2 may provide a new method for re-sensitizing castration-resistant prostate tumors to hormone therapy.
A joint Swedish-UK study found that men who participated in biennial PSA-based screening had lower risks of being diagnosed with and dying from prostate cancer for up to 9 years. After 9 years, the rates in both groups converged, but mortality was significantly lower in the screening group initially.
A Dutch study found that abiraterone can block androgen receptor activation directly, in addition to inhibiting CYP17A1 activity. This suggests a new mechanism of action for treating castration-resistant prostate cancer.
A large observational study conducted by a group of researchers in Sweden and the Netherlands suggests that surgery offers better survival benefits than radiotherapy for men with localized prostate cancer, especially in younger age groups and those with fewer comorbidities. The study found that radical treatment, preferably surgery, is...
Two novel radiolabeled small molecules targeting PSMA have excellent potential for diagnosing and staging prostate cancer. The imaging agents showed a high sensitivity of lesion detection in bone, soft tissue, and the prostate gland.
Researchers have developed a new focal laser ablation treatment that uses precisely targeted heat to burn away cancerous cells in the prostate. The approach has shown promising safety results and can be performed without significant side effects.
A UCLA study found that financial hardship, lack of doctor continuity and care coordination, and communication issues significantly hinder access to prostate cancer care among Latino men. The study highlights the need for a multi-faceted approach to improve access, increase health literacy, and enhance care coordination.
A study published in the Journal of Urology analyzed 25 years of data after radiation therapy for prostate cancer patients and found that follow-up evaluations are necessary for 15 years after treatment. The study also confirmed using radiation therapy results in comparable disease-free survival rates to radical prostatectomy.
A modified Newcastle disease virus has been developed to target prostate cancer cells without harming normal cells, offering a new treatment option for hormone-refractory patients. This oncolytic virus uses a retargeted design to minimize off-target losses and reduce the amount of virus needed for treatment.
A natural product called genistein-combined polysaccharide (GCP) may help patients with metastatic prostate cancer live longer by blocking a key mechanism used by prostate cancer cells to survive. GCP is expected to be effective in treating patients with low response to androgen-deprivation therapy.
A recent study found that radical prostatectomy (RP) lowers prostate cancer deaths in a subgroup of patients with a significant absolute mortality difference. However, another trial showed non-statistically significant results, raising questions about the impact of more frequent screening detection.
Research from the 2013 Genitourinary Cancers Symposium highlights new insights on high-risk prostate cancer prevalence and treatment. Studies show that African-American men and older men of any race are more likely to have aggressive prostate cancer, while surveillance for small kidney tumors is a safe alternative to surgery for elderl...
Early-onset prostate cancers have distinct genetic alterations that link genes normally independent to cancer-causing fusion genes. Androgen hormone receptors are also higher in younger patients, suggesting a potential trigger for the disease.
A recent study has found that exercise is linked with reduced prostate cancer risk in Caucasian men, but no such benefit is seen among African-American men. Furthermore, exercise also appears to lower the risk of high-grade prostate cancer in Caucasians compared to sedentary individuals.
Early-onset prostate cancer is linked to high levels of androgen receptor activity in young patients, leading to gene rearrangements that promote cancer. This discovery could lead to new diagnostic, prognostic, therapeutic, and prevention strategies for the disease.
A study published in JAMA Internal Medicine found that men's decisions to undergo prostate-specific antigen (PSA) screening are influenced by how information is presented. The researchers discovered that men who were given a balance sheet with relevant features of PSA screening were more likely to choose the screening option, while tho...
The Northwell Health system has received a federal grant to train Hampton University students on the racial disparities in prostate cancer treatments. The program aims to improve treatment outcomes for African American men, who are disproportionately affected by the disease.
A previously poorly investigated signalling pathway is crucial for prostate cancer cell proliferation, involving the production of cAMP at multiple locations in the cell. Inhibiting the soluble adenylyl cyclase enzyme suppresses cancer cell growth, suggesting a promising new therapeutic approach.
A recent study published in Annals of Internal Medicine suggests that exercising regularly earlier in life can significantly lower the risk of developing dementia later in life. Researchers analyzed data from over 19,000 adults and found a strong association between midlife fitness levels and reduced risk of all-cause dementia. Additio...
A new radiation therapy method using volume-modulated arc therapy (VMAT) has been shown to significantly reduce prostate cancer treatment time by approximately 14%. The study found that VMAT patients had shorter average room times, with some patients experiencing similar treatment times as those using gold-marker tracking.
A new study found differences in urinary, bowel, and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment. Men who underwent prostatectomy were more likely to experience urinary incontinence and erectile dysfunction.
A recent study by Fred Hutchinson Cancer Center found that regular consumption of deep-fried foods like French fries and doughnuts is associated with a higher risk of prostate cancer. The study suggests that frequent and regular consumption of these foods may be linked to more aggressive forms of the disease.
Researchers found that stress accelerates prostate cancer development in mice, while a genetic mutation in the NESP4 gene disrupts a cellular complex essential for hearing. Combining green tea extract with vardenafil enhances anti-cancer effects in a mouse model of multiple myeloma.
A recent study found that stress can accelerate prostate cancer development in mice, with adrenaline blocking cancer cell death. Conversely, drugs that inhibited adrenaline signaling ablated the effect of stress on prostate cancer. This suggests that beta-blockers could enhance the effectiveness of anti-cancer therapies.
A new study by Wake Forest Baptist researchers found that emotional stress can reduce the effectiveness of prostate cancer therapies and accelerate tumor growth. Stress-induced activation of a cell signaling pathway may lead to a vicious cycle of stress and cancer progression.
A new study finds that prostate cancer stigma is a significant barrier to diagnosis and treatment in Ghana, with many men diagnosed at late stages and opting out of therapy. The researchers aim to develop tailored treatment regimens and increase PSA screening rates to improve health outcomes.
Researchers discovered stable epigenetic marks across all metastatic tumors in each patient, defying the idea that these marks vary greatly within individuals. These consistent methylation changes appear to represent driver changes critical to cancer development and could be targets for treatment.
A two-year observational follow-up of the REDUCE trial found that dutasteride treatment was associated with a lower incidence of new prostate cancers. The study, published in The Journal of Urology, showed that men taking dutasteride had fewer prostate cancer diagnoses compared to those receiving a placebo.
A Kaiser Permanente study found that annual percent changes in prostate-specific antigen (PSA) levels are more accurate for detecting aggressive prostate cancer than single measurements. The study analyzed nearly 220,000 men and found a moderate increase in PSA levels with age.
A high-fiber diet, rich in inositol hexaphosphate (IP6), can control prostate cancer progression by inhibiting tumor growth and slowing glucose metabolism. Researchers found that IP6 reduced tumor volumes and slowed glucose metabolism in prostate cancer models.
A comprehensive study analyzed 232 papers on prostate cancer treatments and found that surgery is the most cost-effective option, saving lives at a lower cost than radiation therapy. The analysis also showed that treatment plans for localized prostate cancer vary dramatically across different centers.
A study by Dana-Farber Cancer Institute found that a small percentage of men treated for prostate cancer reported a perceived shortening of their penis, leading to regrets about treatment choice. The complaint was more common in men treated with radical prostatectomy or male hormone-blocking drugs combined with radiation therapy.
Thomas Jefferson University researchers have identified new pathways that drive aggressive forms of prostate cancer. Elevated levels of Cyclin D1b function as a novel biomarker for lethal metastatic disease in prostate cancer patients.
A preclinical study found that androgen deprivation therapies may have adverse effects on prostate cancer growth and survival in men with precancerous conditions. The study's results suggest that reducing testosterone levels may encourage indolent tumors to become more aggressive as men age.
Researchers at the Kimmel Cancer Center at Jefferson developed diagnostic and prognostic genetic tests to better predict prostate cancer survival outcomes. The tests distinguish clinically-relevant cancers from normal prostate tissue in men with elevated PSA levels, offering a superior alternative to existing gene tests and the Gleason...
Researchers at Mayo Clinic have identified an enzyme specifically linked to aggressive prostate cancer, which promotes the metastatic spread of the disease. A compound that inhibits this enzyme's ability has been developed and shows promise for future clinical applications.
A study published in the Journal of the National Cancer Institute found no significant difference in toxicity between proton radiotherapy (PRT) and intensity-modulated radiotherapy (IMRT) among Medicare beneficiaries with prostate cancer at 12 months post-treatment. Despite its widespread use, PRT's benefits and harms remain unknown.
A new Australian study finds that large regions of the genome are epigenetically activated in prostate cancer, including genes like PSA and PCA3. The study also identifies 'epigenetic master controllers' that can switch on or off large regions of DNA, with significant implications for cancer diagnosis and treatment.
Dana-Farber Cancer Institute scientists identify EZH2 as a key player in prostate cancers that no longer respond to hormone-blocking treatments. The researchers suggest that drugs targeting EZH2's unexpected function could be an effective new treatment strategy for these aggressive cancers.
A new targeted prostate biopsy technique using magnetic resonance ultrasound fusion has been shown to improve diagnosis of prostate cancer and aid in selecting patients for active surveillance. The study found that the biopsies identified 90 out of 171 men with prostate cancer, highlighting its potential as a more accurate and efficien...
A new imaging-guided targeted biopsy method using MRI and ultrasound fusion has been shown to detect prostate cancer more accurately than traditional blind biopsies. The technique led to a high rate of cancer detection and identification of aggressive tumors, improving patient outcomes.
The growing US population and increased life expectancy necessitate new approaches to prostate cancer treatment. Researchers are exploring targeted therapies, immunotherapy, and precision radiation targeting to improve treatment outcomes for older patients.
A new drug demonstrated dramatic effects on prostate cancer that had spread to the bone, with two-thirds of patients showing improvements on their bone scans. Additionally, 67% of patients with bone pain reported improved pain control after treatment with cabozantinib.
Researchers found that high levels of COUP-TFII can overcome a natural barrier to prostate cancer progression, allowing tumor cells to grow and spread throughout the body. The study suggests that COUP-TFII is an important 'second hit' for the progression of prostate cancer and metastasis.
A study of almost 1,000 men diagnosed with prostate cancer found that active surveillance can reduce or avoid side effects such as incontinence and impotence. Many low-risk tumours are slow-growing and may never develop symptoms during a lifetime.
Researchers at Baylor College of Medicine discovered a positive feedback loop between Notch and TGF beta proteins that maintains basal cell population in the prostate. Disrupting this loop may contribute to prostate cancer initiation.
A study by Loyola Medicine found that only 4.8% of web sites describing prostate cancer were written below a high school reading level, highlighting the need for easier-to-read patient education materials.
Researchers have identified a new molecular marker, β2-syntrophin, which can help differentiate between low-risk and high-risk types of prostate cancer. This breakthrough discovery could lead to more accurate diagnoses and personalized treatment plans, ultimately improving patient outcomes.
Men treated with proton therapy for prostate cancer reported excellent urinary and bowel function, similar to healthy controls. However, sexual function was affected by hormone therapy and other factors, with significant differences noted between groups.
Researchers developed a noninvasive assay to monitor treatment response in patients with metastatic prostate cancer. The assay measures androgen receptor signaling pathway activity in circulating tumor cells, allowing for early detection of resistance to treatment.
A new study found that men with high blood pressure, high blood sugar, and a high body mass index are more likely to die from prostate cancer. Researchers also discovered that combining these metabolic factors increases the risk of death, suggesting that lifestyle changes may help prevent this.
A long-term study found that radiotherapy after surgery significantly improves biochemical progression-free survival and local control for high-risk prostate cancer patients. However, its effects on clinical progression-free survival and overall survival are less clear.
Researchers at Queen Mary University of London discovered that the characteristic shape of a man's urine stream can be used to diagnose urinary problems, including those associated with prostate enlargement. The study found a strong correlation between the shape of the urine flow pattern and the maximum urine flow rate.
Researchers found that high levels of activated Stat5 protein in prostate cancer after surgery are associated with increased risk of recurrence and death. The study suggests Stat5 could serve as a biomarker to help guide patients and physicians for future treatment.
Researchers at the University of Missouri have developed a new gold nanoparticle treatment for prostate cancer that uses radioactive gold nanoparticles. The treatment has shown to be safe and effective in dogs, which are the only other mammal to naturally contract aggressive prostate cancer, making it a promising lead for human trials.
Research by Centre INRS–Institut Armand-Frappier and Centre de recherche du Centre hospitalier de l'Université de Montréal found a possible association between night work and increased risk of prostate, colon, lung, bladder, rectal, and pancreatic cancer. Exposure to light at night can disrupt the body's natural sleep-wake cycle.
A new study reveals that curcumin, a compound found in turmeric, can inhibit the formation of metastases in prostate cancer. Curcumin reduces inflammation and decreases the expression of proteins that promote metastasis, resulting in a decline in tumor cell growth.